Angelo Tanna, MD
Ophthalmology · Chicago, ILNPI 1215960489
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $6,573 of the $9,947 with a category attached, or 66.1%. Carl Zeiss Meditec, Inc. accounts for 62.5% of it on its own, with 9 other manufacturers making up the rest. Reporting peaked in 2019 at $3,249 and has fallen 59.4% since, to $1,318 in 2025.
Across 31 payments — averaging $320.85 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Carl Zeiss Meditec, Inc.$6K
- Bausch & Lomb, A Division Of Bausch Health US, LLC$2K
- Johnson & Johnson Surgical Vision, Inc.$500
- Alcon$417
- Aerie Pharmaceuticals, Inc.$379
- AbbVie$155
- plus $280 from 4 others
What the payments were for
- Consulting fees$6,57366%
- Speaking & faculty fees$2,00020%
- Food & beverage$1,35514%
- Gifts$190%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Carl Zeiss Meditec, Inc. | 9 | $6,216 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 1 | $2,000 |
| Johnson & Johnson Surgical Vision, Inc. | 1 | $500 |
| Alcon | 4 | $417 |
| Aerie Pharmaceuticals, Inc. | 4 | $379 |
| AbbVie | 3 | $155 |
| Sight Sciences, Inc. | 3 | $132 |
| Heidelberg Engineering, Inc. | 4 | $107 |
| NEW World Medical,inc. | 1 | $22 |
| Carl Zeiss Meditec AG | 1 | $19 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- PROLENSA$2,000
- LOTEMAX$2,000
- ENVISTA$2,000
- VICTUS$2,000
- STELLARIS$2,000
- CALLISTO eye$1,520
- IOLMaster 700$1,150
- QUATERA 700$1,020
- CIRRUS HD-OCT$1,020
- CIRRUS 6000 with AngioPlex$1,020
- Humphrey HFA$990
- FORUM$650
- FORUM Glaucoma Workplace$650
- Whitestar Phacoemulsficiation System$500
- OPMI Lumera 700$500
- Humphrey Field Analyzer (HFA3)$340
- Hydrus Microstent$189
- Rhopressa$152
- Rocklatan$152
How this compares
$9,947 in reported general payments places this provider in the 85th percentile of 773 ophthalmology providers in Illinois.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| LumiganBimatoprost | 253 | $128,205 |
| RhopressaNetarsudil Mesylate | 195 | $106,526 |
| Alphagan PBrimonidine Tartrate | 130 | $65,923 |
| Brimonidine Tartrate | 800 | $51,941 |
| RocklatanNetarsudil Mesylat/Latanoprost | 72 | $33,882 |
| VyzultaLatanoprostene Bunod | 68 | $30,777 |
| Latanoprost | 1,945 | $26,370 |
| Brinzolamide | 121 | $25,172 |
| SimbrinzaBrinzolamide/Brimonidine Tart | 74 | $22,385 |
| Travoprost | 119 | $19,612 |
| RestasisCyclosporine | 23 | $19,543 |
| Timolol MaleateTimolol Maleate/Pf | 52 | $16,593 |
| Travatan ZTravoprost | 29 | $16,330 |
| AzoptBrinzolamide | 25 | $14,888 |
| Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol | 69 | $14,394 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieLumigan, Alphagan P, Restasis, Combigan | $155 | $221,125419 claims |
| Aerie Pharmaceuticals, Inc.Rhopressa, Rocklatan | $379 | $140,408267 claims |
| AlconSimbrinza, Azopt | $417 | $37,27399 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 773 ophthalmology providers in Illinois.
Other ophthalmology in Chicago
- Seenu HariprasadChicago$2.3M
- Yannek LeidermanChicago$312K
- Asim FarooqChicago$270K
- Dilraj GrewalChicago$188K
- Ahmad ArefChicago$179K
- Robert SchroederChicago$153K
- Jennifer LimChicago$150K
- Surendra BastiChicago$126K
- Allen PuttermanChicago$94K
- Maria CortinaChicago$88K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.